Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2022-11-24 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于第五届监事会第五次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at the fifth meeting of the fifth Supervisory Board of 特一药业集团股份有限公司. It details decisions regarding the cancellation of part of the 2021 stock option incentive plan and the approval of the first exercise period conditions for the 2021 stock option plan. The document includes voting results and confirms compliance with relevant laws and company regulations. It is not a full financial report, audit report, or earnings release, but rather a formal announcement of board-level decisions related to stock options and incentive plans. This fits best under the category of Regulatory Filings (RNS), as it is a regulatory announcement about corporate governance matters and stock option plan adjustments, not a full management or financial report.
2022-11-24 Chinese
监事会关于2021年股票期权激励计划有关事项的核查意见
Remuneration Information Classification · 85% confidence The document is a supervisory board's verification opinion regarding the 2021 stock option incentive plan of the company. It discusses the cancellation of certain stock options due to retirement or resignation of incentive recipients and confirms that the conditions for the first exercise period of the stock option plan have been met. The document includes legal and regulatory references and is a formal opinion or verification statement by the supervisory board. It is not a full annual report, earnings release, or financial statement. It is also not a simple announcement or a proxy solicitation. The content focuses on stock option incentive plan matters, which relate to remuneration and compensation. However, it is specifically a supervisory board's verification opinion on stock option incentive plan matters, which aligns best with Remuneration Information filings that detail executive and key personnel compensation plans and related approvals. The document length is short (1373 characters), and it contains substantive content rather than just an announcement or certification. Therefore, the best classification is Remuneration Information (DEF 14A).
2022-11-24 Chinese
关于第五届董事会第五次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board meeting of the company 特一药业集团股份有限公司. It details the meeting date, attendance, and specific decisions made regarding the stock option incentive plan, including cancellation of some stock options and approval of exercise conditions. The document does not contain financial statements or detailed financial analysis but rather reports on board decisions. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting results announcement. The document is a formal announcement of board/management decisions, specifically about stock option plans, which falls under Board/Management Information (MANG). The document length is short (1256 characters), and it is not a report publication announcement or regulatory filing. Therefore, the best classification is MANG with high confidence.
2022-11-24 Chinese
国浩律师（深圳）事务所关于特一药业2021年股票期权激励计划注销部分股票期权及第一个行权期行权条件成就的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the company's 2021 stock option incentive plan, specifically about the cancellation of some stock options and the achievement of the first exercise period conditions. It discusses approvals by the board, supervisory board, and shareholders, details about the stock option plan, exercise conditions, and legal compliance. The document is a standalone legal opinion related to stock option incentive plan matters, not a full annual or interim financial report, nor an announcement of voting results or a proxy statement. It is not a transcript, earnings release, or capital update. It is a legal proceeding related document but more specifically a legal opinion letter on stock option plan compliance and exercise conditions. Given the nature of the document as a legal opinion letter, it fits best under Legal Proceedings Report (LTR).
2022-11-24 Chinese
2021年股票期权激励计划第一个行权期可行权激励对象名单
Director's Dealing Classification · 95% confidence The document is a detailed announcement listing the names and stock option quantities of individuals eligible to exercise stock options under the company's 2021 stock option incentive plan. It includes specific data on the number of options granted and exercisable, as well as the proportion relative to total shares. This type of document is related to insider or management share transactions, specifically the exercise of stock options by directors and key personnel. It is not a full financial report, earnings release, or regulatory filing about financial results. It is also not a general announcement or proxy material. The closest fitting category is 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives, including stock option exercises. The document length is short (2401 characters), and it contains substantive data about share transactions by insiders, not just an announcement or certification. Therefore, the classification is DIRS with high confidence.
2022-11-24 Chinese
关于2021年股票期权激励计划第一个行权期行权条件成就的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the achievement of conditions for the first exercise period of its 2021 stock option incentive plan. It details the approval process, conditions met, exercise arrangements, and legal and supervisory opinions. The content focuses on stock option exercise conditions, approvals, and related corporate governance matters. It is not a full financial report, earnings release, or management discussion, but rather a formal announcement about stock option exercise conditions and related corporate actions. This fits best under the category of Regulatory Filings (RNS), as it is a regulatory announcement about stock option exercise conditions and approvals, not a full report or financial statement.
2022-11-24 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.